A Review of trabectedin (ET-743): A unique mechanism of action

Molecular Cancer Therapeutics

Volumn 9, Issue 8, 2010, Pages 2157-2163

  D'Incalci, Maurizio ^a   Galmarini, Carlos M ^b  

^a Istiuto di Ricerche Farmacologiche Mario Negri ^*  (Italy)

^b Cell Biology Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CCAAT BINDING FACTOR; CISPLATIN; DISTAMYCIN A; DNA BINDING PROTEIN; DOUBLE STRANDED DNA; DOXORUBICIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; OXALIPLATIN; PACLITAXEL; RACHELMYCIN; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; DNA ADDUCT; DNA HELIX; DNA REPAIR; DRUG DNA BINDING; DRUG POTENTIATION; DRUG STRUCTURE; ECTEINASCIDIA TURBINATA; EXCISION REPAIR; HUMAN; HYDROGEN BOND; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT;

ANIMALS; DIOXOLES; DNA; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; TETRAHYDROISOQUINOLINES;

EID: 77955505177     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0263     Document Type: Review

References (40)

1. Cuevas C, Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep 2009;26:322-37.
2. Gago F, Hurley LH. Devising a structural basisfor the potent cytotoxic effects of ecteinascidin 743. In: Demeunynck M, Bailly C, Wilson WD, editors. Small molecule DNA and RNA binders: From synthesis to nuclear acid complexes. Weinheim, Germany: Wiley-VCH; 2002, p. 643-75.
3. Hurley LH, Zewail-Foote M. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability. Adv Exp Med Biol 2001;500:289-99. (Pubitemid 34107018)
4. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105.
5. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
6. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-8.
7. Damia G, D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007;43:1791-801. (Pubitemid 47238245)
8. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-Talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155-62.
9. Erba E, Cavallaro E, Damia G, et al. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog PM00128 which lacks the C ring. Oncol Res 2004;14:579-87.
10. Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 2007;104:13062-7.
11. Tavecchio M, Simone M, Erba E, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008;44:609-18.
12. Tercero JC, Jimeno J, Martinez N, Montes-Moreno S, Rodriguez-Pinilla SM, Sanchez-Beato M. Predicting sarcoma patients response to trabectedin treatment with molecular markers detected by immunohistochemistry [abstract]. Third AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development; 2008 Sep 22-25; Philadelphia, PA. Philadelphia (PA): AACR; 2008, p. 44. Abstract nr B28.
13. Guirouilh-Barbat J, Redon C, Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 2008;19:3969-81.
14. Casado JA, Rio P, Marco E, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008;7:1309-18.
15. Bonfanti M, La Valle E, Fernandez Sousa Faro JM, Faircloth G, Caretti G, D'Incalci M. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999; 14:179-86. (Pubitemid 29428023)
16. Broggini M, D'Incalci M. Modulation of transcription factor - DNA interactions by anticancer drugs. Anticancer Drug Des 1994;9:373-87. (Pubitemid 24297533)
17. Scotto KW. ET-743: more than an innovative mechanism of action. Anticancer Drugs 2002;13[Suppl 1]:S3-6.
18. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000;97:6780-4.
19. Jin S, Gorfajn B, Faircloth G, Scotto KW. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 2000;97:6775-9.
20. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002;62:3377-81. (Pubitemid 34651382)
21. Minuzzo M, Ceribelli M, Pitarque-Marti M, et al. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol 2005;68:1496-503.
22. Aune GJ, Takagi K, Sordet O, et al. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res 2008;14:6449-55.
23. Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005;65:2964-71.
24. Germano G, Frapolli R, Simone M, et al. Antitumor and antiinflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010;70:2235-44.
25. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602.
26. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20:1439-44.
27. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 2004;155:1-24. (Pubitemid 39446608)
28. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009;8:449-57.
29. Griffin LB, Grohar P, Pommier Y, Khanna C, Khan J, Helman LJ. ET-743 modulates EWS-FLi1 activity in Ewing's sarcoma cells [abstract]. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver (CO). Philadelphia (PA): AACR; 2009. Abstract nr 1501.
30. Aune GJ, Furuta T, Pommier Y. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs 2002;13:545-55.
31. Marchini S, Marrazzo E, Bonomi R, et al. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur J Cancer 2005; 41:323-33.
32. Shao L, Kasanov J, Hornicek FJ, Morii T, Fondren G, Weissbach L. Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. Biochem Pharmacol 2003;66:2381-95. (Pubitemid 37460995)
33. Erba E, Bergamaschi D, Bassano L, et al. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 2000;82:1732-9.
34. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001;7:3251-7.
35. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003;52:131-8.
36. Scotlandi K, Perdichizzi S, Manara MC, et al. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 2002;8:3893-903. (Pubitemid 35428818)
37. Erba E, Muratore I, Tiozzo G, Ubezio P, Colombo T, Nicoletti I. ET-743 and cisplatin (DDP) show in vitro and in vivo synergy against human sarcoma and ovarian carcinoma cell lines. Clin Cancer Res 2001;7 Suppl:A406.
38. Erba E, Colombo T, Ubezio P, Ferrarese L, Matera G, Falcioni C. Combination of Yondelis (ET-743) and oxaliplatin in experimental ovarian cancer. Clin Cancer Res 2003;9Suppl:C247.
39. Takahashi N, Li W, Banerjee D, et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 2002;62:6909-15. (Pubitemid 35424080)
40. D'Incalci M, Colombo T, Ubezio P, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003;39:1920-6. (Pubitemid 37311190)